Galapagos lands $150M bounty in $1.35bn autoimmune deal with Abbott
This article was originally published in Scrip
Executive Summary
Galapagos, the profitable mid-sized European biotech, has signed up Abbott Laboratories as its partner to develop and commercialise an oral, next-generation Janus kinase (JAK) 1 inhibitor in multiple autoimmune diseases, including rheumatoid arthritis.